PlumX Metrics
Embed PlumX Metrics

Defining the role of GLP-1 receptor agonists for individualized treatment of type 2 diabetes

Expert Review of Endocrinology and Metabolism, ISSN: 1744-8417, Vol: 9, Issue: 6, Page: 659-670
2014
  • 13
    Citations
  • 0
    Usage
  • 22
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Review Description

With the advent of dipeptidyl peptidase (DPP)-4 inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) over the past decade, incretin therapy has become established as an important treatment strategy for Type 2 diabetes mellitus (T2DM), with an efficacy and safety profile distinct from that of other anti-hyperglycemic agents. However, our understanding of the optimal clinical use of incretins remains incomplete. This review focuses on the use of GLP-1 RAs in the treatment of T2DM, with reference to the differing dominant mechanisms of action between short-and long-acting GLP-1 RAs and the clinical implications of this difference. The role of GLP-1 and the effects of GLP-1 RAs in various organs other than the pancreas will also be discussed.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know